Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cleveland Life Science Advisors (CLSA) is an investment organization based in Cleveland, focused on early-stage ventures in the life sciences sector. The firm aims to leverage the potential of Cleveland and the Greater Midwest, targeting companies that can significantly impact patient care. CLSA manages a portfolio of 10 companies, emphasizing strategic buyouts and IPOs within a 3-5 year timeframe.
CLSA invests in early-stage biotech and healthcare companies that demonstrate exceptional market opportunities and strong intellectual property. The firm targets pre-seed to Series A stages, seeking technologies that lead to transformative healthcare advancements. Their investment strategy includes both financial returns and humanitarian impact.
Notable portfolio companies include: Hemex Health, which developed the Gazelle™ diagnostic platform for blood disorders, achieving significant sales growth and deployment of over 1.2 million tests across 30 countries; Luminary Therapeutics, focusing on a next-generation CAR-T platform for cancer therapies; and Prima Medical, which is enhancing catheter ablation procedures with AI technology. Other companies include Neucore Bio, Tevard Biosciences, careMESH, Convelo Therapeutics, BIOHM, Vitranu, and Deep Blue.
Submit your pitch through their form at clsafund.com or email info@clsafund.com with your deck.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.